Septerna (SEPN) grants Chief Medical Officer 125,000 stock options

Q: What did Septerna (SEPN) disclose in this Form 4 filing?

Septerna disclosed that its Chief Medical Officer, Kim Jae B. , received a new stock option grant. The award covers 125,000 shares of common stock, granted on February 6, 2026 , with vesting tied to continued service with the company over several years.

Q: How many Septerna stock options were granted to Kim Jae B.?

The filing reports that 125,000 stock options were granted to Chief Medical Officer Kim Jae B. . These options give the right to buy up to 125,000 shares of Septerna common stock, subject to the vesting schedule and the stated exercise price conditions.

Q: What is the exercise price of the new Septerna stock options?

The stock option granted to Kim Jae B. has an exercise price of $25.41 per share. This means Kim can purchase Septerna common stock at $25.41 per share once the options vest and become exercisable, assuming continued service with the company.

Q: When do the Septerna options granted to Kim Jae B. start vesting?

Vesting begins on March 1, 2026 , when 2/48 of the granted options become exercisable. The remaining portion of the 125,000 options vests in 46 substantially equal monthly installments on each monthly anniversary, conditioned on Kim’s continuous service with Septerna.

Q: How many Septerna derivative securities does Kim Jae B. own after this transaction?

Following the reported transaction, Kim Jae B. beneficially owns 125,000 stock options directly. These options relate to Septerna common stock and represent the full amount of derivative securities reported as beneficially owned after the grant in this Form 4 filing.

Q: What role does Kim Jae B. hold at Septerna (SEPN)?

The filing identifies Kim Jae B. as an officer of Septerna, serving as Chief Medical Officer . This executive role typically oversees clinical development and medical strategy, and the reported stock option grant represents part of Kim’s equity-based compensation package from the company.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Septerna’s Chief Medical Officer, Kim Jae B., reported receiving a new stock option award in common stock. On February 6, 2026, a stock option covering 125,000 shares was granted with an exercise price of $25.41 per share.

According to the vesting terms, 2/48 of the option will vest and become exercisable on March 1, 2026. The remaining shares will vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, contingent on Kim’s continuous service with Septerna. After this grant, Kim holds 125,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kim Jae B.

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	125,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 125,000 shares (Direct)

Footnotes (1)

[object Object]

Form 4 Insider Transactions: What Each Field Means →

02/10/2026 - 07:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kim Jae B.

(Last)

(First)

(Middle)

C/O SEPTERNA, INC.

250 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Septerna, Inc. [ SEPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$25.41	02/06/2026		A		125,000		⁽¹⁾	02/05/2036	Common Stock	125,000	$0	125,000	D

Explanation of Responses:

1. 2/48th of the shares subject to such option shall vest and become exercisable on March 1, 2026 and the remaining shares subject to the option shall vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24.2 - Substitute Power of Attorney

	/s/ Mark A. Wilson, Attorney-in-Fact	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Septerna (SEPN) disclose in this Form 4 filing?

Septerna disclosed that its Chief Medical Officer, Kim Jae B., received a new stock option grant. The award covers 125,000 shares of common stock, granted on February 6, 2026, with vesting tied to continued service with the company over several years.

How many Septerna stock options were granted to Kim Jae B.?

The filing reports that 125,000 stock options were granted to Chief Medical Officer Kim Jae B.. These options give the right to buy up to 125,000 shares of Septerna common stock, subject to the vesting schedule and the stated exercise price conditions.

What is the exercise price of the new Septerna stock options?

The stock option granted to Kim Jae B. has an exercise price of $25.41 per share. This means Kim can purchase Septerna common stock at $25.41 per share once the options vest and become exercisable, assuming continued service with the company.

When do the Septerna options granted to Kim Jae B. start vesting?

Vesting begins on March 1, 2026, when 2/48 of the granted options become exercisable. The remaining portion of the 125,000 options vests in 46 substantially equal monthly installments on each monthly anniversary, conditioned on Kim’s continuous service with Septerna.

How many Septerna derivative securities does Kim Jae B. own after this transaction?

Following the reported transaction, Kim Jae B. beneficially owns 125,000 stock options directly. These options relate to Septerna common stock and represent the full amount of derivative securities reported as beneficially owned after the grant in this Form 4 filing.

What role does Kim Jae B. hold at Septerna (SEPN)?

The filing identifies Kim Jae B. as an officer of Septerna, serving as Chief Medical Officer. This executive role typically oversees clinical development and medical strategy, and the reported stock option grant represents part of Kim’s equity-based compensation package from the company.